Clinical Trial Update: China Post-marketing Surveillance (PMS) Study of Fabrazyme® [Phase 4]

View source ↗

Summary

A Phase 4 post-marketing surveillance study of Fabrazyme (agalsidase beta) for Fabry disease in China has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• FABRAZYME (Agalsidase beta)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Fabry Disease | Phase 4 | Status: COMPLETED